• 제목/요약/키워드: Parotid malignancy

검색결과 46건 처리시간 0.017초

점액표피양 암종의 세침흡인 세포학적 소견 (Fine Needle Aspiration Cytology of Mucoepidermoid Carcinoma of the Salivary Gland)

  • 문정석;오화은;이주한;김애리;김철환;김한겸;박미자;원남희
    • 대한세포병리학회지
    • /
    • 제8권2호
    • /
    • pp.135-142
    • /
    • 1997
  • Mucoepidermoid carcinoma is the most common malignant neoplasm of the salivary gland, compring between 30 and 40%. Fine needle apsiration cytology was performed in five patients with mucoepidermoid carcinoma. The patients consisted of three males aged of 42, 48, and 60 years, and two females aged 36, and 56 years. The primary tumor sites were the parotid gland in four patients and the submandibular gland in the rest one. The histologic grades were low in one patient, intermediate in two patients and high in other two. In our experience, the common cytologic findings of low grade subtype were predominent mucous cells with some intermediate cells in an abundant mucinous background. The cytologic findings of intermediate grade subtype were predominant clusters of intermediate cells with or without mucous cells in an abundant mucinous background. And the cytologic findings of high grade subtype were predominant clusters of epidermoid cells with intermediate cells in a bloody background. Cytologic pleomorphism and atypia were more severe in high grade than low and intermediate grade, and nucleoli were more frequently noted in epidermoid cells. In low grade, it is very difficult to decide the benignancy or malignancy of the tumor. In fact, the presence of mucous cells in a mucinous background should rule out any other type of well differentiated carcinoma.

  • PDF

악성 혼합종의 임상적 고찰 (Malignant Mixed Tumor of Salivary Glands: A Clinical Study)

  • 오경균;이국행;이종호;심윤상
    • 대한두경부종양학회지
    • /
    • 제9권2호
    • /
    • pp.227-233
    • /
    • 1993
  • For malignant neoplasms of salivary tissues. two of the better determinants of progosis are histologic classification and size of the neoplasm. Proper management of these tumors requires an accurate diagnosis by the pathologist and correct interpretation by the surgeon. Malignant mixed tumors account for between 3 and 13 precent of all cancers of the salivary glands and 2 percent of all tumors in these locations. The typical history of these tumors is that of slowly growing mass demonstrating a sudden increase in growth. The duration of onset of the tumor mass and the diagnosis of malignancy has been demonstrated to be 10 to 18 years. The risk of malignat transformation of a benign mixed tumor increases with the duration of the tumor. We analyzed retrospectively 13 cases of malignant mixed tumor who visited from Jan. 1985 to Dec. 1992. Mean age of the patients was 56.5 years. The origin of tumors were parotid gland 7 cases, submandibular gland 2 cases, and minor salivary gland 4 cases(palate 3 cases, tonsil pillar 1 case). According to the criteria of the AJCC on staging, stage I was 1 case, stage II 1 case, stage III 2 cases, and stage IV 9 cases. Histopathologically, carcinma ex pleomorphic adenoma were 12 cases and the true malignant mixed tumor was 1 case. The major treatment modalities were curative surgery, and radiation therapy followed. In conclusion, aggressive therapy of combined surgery and postoperative radiation therapy is required for these lesions, and patients with known or suspected benign tumor should be encouraged to undergo surgery early on in their disease to avoid malignant degeneration at a later dete.

  • PDF

Ten Year Experience with Surgery and Radiation in the Management of Malignant Major Salivary Gland Tumors

  • Iqbal, Hassan;Bhatti, Abu Bakar Hafeez;Hussain, Raza;Jamshed, Arif
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권5호
    • /
    • pp.2195-2199
    • /
    • 2014
  • Background: Despite being rare in incidence, malignant tumors of major salivary glands show diverse histological variation. There are limited data on major salivary gland tumor management and outcome from Pakistan. The objective of this study was to share our experience with management of malignant tumors of major salivary glands. Materials and Methods: Patients who received treatment at Shaukat Khanum Cancer Hospital and Research Center from July 2002 to June 2011 with an underlying diagnosis of a major salivary gland malignancy were included. Patient characteristics and treatment modalities were assessed. Local, regional and distant failures were determined. Disease free survival (DFS) and overall survival (OS) were calculated using Kaplan Meier curves and the Log rank test was used to determine statistical significance. Univariate and multivariate analyses were performed using Cox proportional hazard regression. Results: The parotid gland was the primary site of origin in 104 (80%) patients. Mucoepidermoid carcinoma (43%) and adenoid cystic carcinoma (24%) were the most common histological types. Surgery followed by adjuvant radiation remained the mainstay treatment modality with 81 (62%) patients. Nineteen (15%) patients were treated with surgery alone and 30 (23%) patients with locally advanced surgically inoperable tumors received radiation only. Forty one (32%) patients failed the treatment (local 12, regional 11, locoregional 5, distant 13). The expected 5 year DFS and OS were 65% and 74% respectively. On multivariate analysis, grade was the only independent predictor of DFS and nodal involvement was the only independent predictor of overall survival. Conclusions: Employing existing standards of treatment, comparable survival can be achieved in Pakistani population with major salivary gland malignancies as elsehwere in the world.

악하선에 발생한 미만성 대형 B세포 림프종 1례 (Diffuse Large B Cell Lymphoma in Submandibular Gland)

  • 이창행;최지훈;백승국;우정수;정광윤
    • 대한두경부종양학회지
    • /
    • 제19권1호
    • /
    • pp.67-70
    • /
    • 2003
  • Out of entire salivary tumor, 1.7% are malignant lymphoma developed in salivary gland and it is usually mucosa associated lymphoid tissue (MALT) lymphoma developed in salivary gland. In the case of Non-Hodgkin lymphoma, the most frequently involved extanodal sites of diffuse large B cell lymphoma are bone, skin, thyroid, gastrointestinal tract, and lung. Development in salivary gland is very rare. A 69 years old male patient who have found Lt. submandibular gland (SMG) mass a month ago is suspected of malignancy from his FNA result, so histologic exam by SMG resection was operated. According to histopathologic exam, large B cell lymphocyte infiltratration were generally shown as diffuse and lymphoepitheliallesion were not found. In immunostaining, CD79a showed positive and CD3, CAM5.2 showed negative which diagnosed as diffuse large B cell lymphoma. As Ann Arbor stage I, CEOP-B chemotherapy was used 3 times as treatment without any recurrence. In the case of malignant lymphoma in salivary gland, it develops as painless mass in ipsilateral side. If found in parotid gland, it is rare to have facial nerve falsy and pathologically diagnosed as lymphocytes of abnormal type of monoclonal immunostaining must be provided as evidence. Combined therapy is known as most effective treatment for intermediate grade.

트라스투주맙 치료에 반응을 보인 HER2/neu 양성 전이성 타액관 암종 1예 (Trastuzumab in a Patient with Metastatic Salivary Duct Carcinoma : A Case Report)

  • 공봉한;이지은;최상수;박진희;김연실;김민식;이연수;이지연;홍숙희;강진형
    • 대한두경부종양학회지
    • /
    • 제30권2호
    • /
    • pp.90-94
    • /
    • 2014
  • Salivary duct carcinoma(SDC) is rare malignancy, accounting for approximately 1-3% of all malignant salivary gland tumors. Systemic chemotherapy has been used for stage IV SDC, but there is no consensus on the standard treatment. SDC is histologically similar to ductal carcinoma of breast and often overexpress HER2/neu, hence HER2/neu targeted therapy could be one of treatment options. A 75-year-old Arabian man was diagnosed as SDC of right parotid gland with extensive metastases. He received oral 5-FU as palliative chemotherapy, but he was intolerable to oral chemotherapy due to severe oral mucositis. Considering immunohistochemical stain of tumor tissue showing strong positive for HER2/neu, we decided to administer an anti-HER2/neu antibody, trastuzumab. Follow-up CT scans before the third dose of trastuzumab demonstrated remarkable regression of multiple metastases as well as primary tumor. This case suggests that HER2/neu targeted therapy may be a potential therapeutic option for the SDC patient with overexpression of HER2/neu.

Facial Nerve Repair following Acute Nerve Injury

  • Fliss, Ehud;Yanko, Ravit;Zaretski, Arik;Tulchinsky, Roei;Arad, Ehud;Kedar, Daniel J.;Fliss, Dan M.;Gur, Eyal
    • Archives of Plastic Surgery
    • /
    • 제49권4호
    • /
    • pp.501-509
    • /
    • 2022
  • Background Acute facial nerve iatrogenic or traumatic injury warrants rapid management with the goal of reestablishing nerve continuity within 72 hours. However, reconstructive efforts should be performed up to 12 months from the time of injury since facial musculature may still be viable and thus facial tone and function may be salvaged. Methods Data of all patients who underwent facial nerve repair following iatrogenic or traumatic injury were retrospectively collected and assessed. Paralysis etiology, demographics, operative data, postoperative course, and outcome were examined. Results Twenty patients underwent facial nerve repair during the years 2004 to 2019. Data were available for 16 of them. Iatrogenic injury was the common category (n = 13, 81%) with parotidectomy due to primary parotid gland malignancy being the common surgery (n = 7, 44%). Nerve repair was most commonly performed during the first 72 hours of injury (n = 12, 75%) and most of the patients underwent nerve graft repair (n = 15, 94%). Outcome was available for 12 patients, all of which remained with some degree of facial paresis. Six patients suffered from complete facial paralysis (50%) and three underwent secondary facial reanimation (25%). There were no major operative or postoperative complications. Conclusion Iatrogenic and traumatic facial nerve injuries are common etiologies of acquired facial paralysis. In such cases, immediate repair should be performed. For patients presenting with facial paralysis following previous surgery or trauma, nerve repair should be considered up to at least 6 months of injury. Longstanding paralysis is best treated with standard facial reanimation procedures.